FDMT - MCAP CO - 4D Molecular Therapeutics

4D Molecular Therapeutics (FDMT) is a pioneer in the development of gene therapies, leveraging its proprietary IT system for DNA vector maturation. The company is currently expanding its pipeline of cardiac and vision therapies, advancing them toward final-stage trials. This price chart, confirming the market valuation, reflects a capitalization of 0.80. Patient safety is ensured through strict adherence to temperature controls during the transport of biomaterials.

The Therapeutic Vector Evolution platform and patents for custom vectors provide 4D Molecular Therapeutics (FDMT) with significant competitive advantages in gene therapy. The company's current market capitalization aggregates the market price of all shares, determining the total value of the business. Analyzing this metric allows for the identification of whether the asset is overvalued or undervalued relative to its fundamental potential. This chart reflects investor confidence in the issuer's intellectual property. Stable capitalization confirms the resilience of the business model.